Birketts advises Pharma-Data S.A. on acquisition by Rosemont
6 August 2024
Birketts has advised the shareholders of Pharma-Data S.A. on its sale to Rosemont Pharmaceuticals Ltd.
Pharma-Data specialises in Research and Development and development of Value-Added Medicinal Drug Products for Europe and USA. With a laboratory in Lavrion, Greece and global services in contract development, dossier writing, technology transfer, licensing and regulatory services, the organisation complements Rosemont’s extensive product development capability.
With over 50 years of expertise, Rosemont is a leading developer, manufacturer and distributor of oral liquid medicines and a supplier of solutions to over 27 international markets. The acquisition was Rosemont’s first step towards having international affiliates beyond the United Kingdon and was quickly followed up by the acquisition of US based Sabal Therapeutics.
The Birketts team advising Pharma-Data was led by Matthew Stratton (Partner, Corporate) and supported by Grace Shek (Corporate), Jen Banfield (Corporate), Karl Pocock (Corporate Tax), Robbie Watson (Corporate Tax), Abbie Head (Employment), Nick West (Employment), Anousha Davies (Intellectual Property), and Maria Peyman (Intellectual Property).
On completing the transaction, Matthew Stratton, Partner in Birketts’ Corporate Team, said: “We were delighted to have partnered with Yannis Psarrakis and the Pharma-Data team on this new era for the organisation. Together, Rosemont and Pharma-Data will continue to push the boundaries in developing new therapeutic medicines, and we’re wishing them both the very best for the future.”
Yannis N. Psarrakis, Managing Director of Pharma-Data, added: “We are pleased to be working with Matthew Stratton and the whole Birketts team as we move to this new epoch of Pharma-Data’s coexistence and coevolution with Rosemont Pharmaceuticals. Myself and the other shareholders are grateful to Birketts for their support and expertise throughout the transaction.”